Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A Rare Presentation of Infantile Virilization Secondary to Malignant Etiology.

Nagesh VD, Santosh DR, Sravya ND.

Indian J Surg Oncol. 2017 Jun;8(2):203-205. doi: 10.1007/s13193-016-0581-6. Epub 2016 Nov 18.

PMID:
28546721
2.

Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.

Millis SZ, Ejadi S, Demeure MJ.

Biomark Cancer. 2015 Dec 17;7:69-76. doi: 10.4137/BIC.S34292. eCollection 2015.

3.

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.

Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM.

BMC Cancer. 2014 Aug 2;14:561. doi: 10.1186/1471-2407-14-561.

4.

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.

Ross JS, Wang K, Rand JV, Gay L, Presta MJ, Sheehan CE, Ali SM, Elvin JA, Labrecque E, Hiemstra C, Buell J, Otto GA, Yelensky R, Lipson D, Morosini D, Chmielecki J, Miller VA, Stephens PJ.

J Clin Pathol. 2014 Nov;67(11):968-73. doi: 10.1136/jclinpath-2014-202514. Epub 2014 Jul 30.

5.

Gene expression and regulation in adrenocortical tumorigenesis.

Fonseca AL, Healy J, Kunstman JW, Korah R, Carling T.

Biology (Basel). 2012 Dec 27;2(1):26-39. doi: 10.3390/biology2010026.

6.

Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.

Korah R, Healy JM, Kunstman JW, Fonseca AL, Ameri AH, Prasad ML, Carling T.

Mol Cancer. 2013 Aug 5;12:87. doi: 10.1186/1476-4598-12-87.

7.

A rare coexistence of non-functional adrenocortical carcinoma and multicentric papillary thyroid microcarcinoma: a case report.

Karakose M, Hasdemir O, Cakal E, Delibasi T.

J Med Case Rep. 2013 Jul 26;7:200. doi: 10.1186/1752-1947-7-200.

8.

Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.

Lebastchi AH, Kunstman JW, Carling T.

J Oncol. 2012;2012:234726. doi: 10.1155/2012/234726. Epub 2012 Oct 18.

9.

Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.

Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, Fragoso MC, Kuick R, Lerario AM, Simon DP, Soares IC, Starnes E, Thomas DG, Latronico AC, Giordano TJ, Hammer GD.

Am J Pathol. 2012 Sep;181(3):1017-33. doi: 10.1016/j.ajpath.2012.05.026. Epub 2012 Jul 15.

10.

Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes.

Herbet M, Salomon A, Feige JJ, Thomas M.

PLoS Genet. 2012;8(5):e1002700. doi: 10.1371/journal.pgen.1002700. Epub 2012 May 10.

11.

DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors.

Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS, Kebebew E.

J Clin Endocrinol Metab. 2012 Jun;97(6):E1004-13. doi: 10.1210/jc.2011-3298. Epub 2012 Apr 3.

12.

mRNA and microRNA expression patterns in adrenocortical cancer.

Zsippai A, Szabó DR, Szabó PM, Tömböl Z, Bendes MR, Nagy Z, Rácz K, Igaz P.

Am J Cancer Res. 2011;1(5):618-28. Epub 2011 Apr 25.

13.

Current and emerging therapies for advanced adrenocortical carcinoma.

Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB.

Oncologist. 2011;16(1):36-48. doi: 10.1634/theoncologist.2010-0270. Epub 2011 Jan 6. Review.

14.

Adrenocortical carcinoma and synchronous malignancies.

Guerrero MA, Kebebew E.

J Cancer. 2010 Aug 12;1:108-11.

15.

Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.

Suh I, Weng J, Fernandez-Ranvier G, Shen WT, Duh QY, Clark OH, Kebebew E.

Arch Surg. 2010 Mar;145(3):226-32. doi: 10.1001/archsurg.2009.292.

Supplemental Content

Support Center